OriCiro Genomics
Latest round
- Series B
Last raised
- Jul 2021
Total raised
- $11M
Investors
- 2
About OriCiro Genomics
Based in Japan, established in 2018, OriCiro Genomics operates as a life science company aiming to realize a better bioeconomy through the provision of innovative DNA technology. OriCiro® Cell, the first research reagent kit for cell-free long-chain DNA amplification, is based on an epoch-making original technology that can amplify large-sized DNA without using cells. OriCiro launched the Free Cloning System in the summer of 2020.coli transformation and culture. This product can not only streamline your workflow dramatically but also widen the scope of your genetic engineering techniques. This product is composed of OriCiro® Assembly Kit and OriCiro® Amp Kit and is designed to produce the maximum effect when used in combination although each kit can be used independently. In the OriCiro® Assembly Kit, DNA fragments are assembled via overlapping ends having homologous sequences. First, each end of the fragments is digested by exonucleases to expose a single-stranded homologous sequence. Then, corresponding fragments having the homologous sequence are annealed by enzymes. The kit assembles up to 50 DNA fragments simultaneously in a single isothermal enzymatic reaction. The assembly products are subjected directly to OriCiro® Amp Kit for selective amplification of your target circular DNA. The OriCiro® Amp Kit contains 26 kinds of purified enzymes that are essential for the E. coli chromosome replication cycle. This Kit enables amplifying exponentially circular DNA having oriC (E. coli chromosomal origin) in an isothermal condition even from a single template molecule. Up to 1 µg of circular DNA can be yielded as supercoiled form per 10 µl reaction. OriCiro Genomics Inc.
Who invested in OriCiro Genomics
2 investors across 2 rounds
See all investors in OriCiro Genomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OriCiro Genomics
Who invested in OriCiro Genomics?
OriCiro Genomics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OriCiro Genomics raised?
OriCiro Genomics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did OriCiro Genomics last raise money?
OriCiro Genomics's most recent round on record is a Series B, in Jul 2021.
What does OriCiro Genomics do?
Based in Japan, established in 2018, OriCiro Genomics operates as a life science company aiming to realize a better bioeconomy through the provision of innovative DNA technology.
Where is OriCiro Genomics headquartered?
OriCiro Genomics is headquartered in Tokyo, Japan.
Which VCs invest in companies like OriCiro Genomics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at OriCiro Genomics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like OriCiro Genomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.